We are harnessing the full potential of our proprietary Trimer-Tag© platform technology to target trimerization-dependent pathways involved in the pathology of a spectrum of major diseases.
Innovation is the driving force for the continuous advancement of Clover Biopharmaceuticals. We develop and deliver brand new medicines to treat society’s most debilitating diseases and meet urgent public health needs around the world.
We believe in the C.L.O.V.E.R. values of being Collaborative, Loving, Open, Visionary, Ethical and Resilient. As we establish Clover as a global leader in the discovery, development and delivery of breakthrough therapies, we continue to seek dedicated, talented and highly motivated people with diverse backgrounds to join us in our mission to bring novel biologic therapies to patients globally.
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate